MedTrace Logo

Effects of PAP Treatment of OSA in Patients With Heart Failure

NCT01136122 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-10-20

No results posted yet for this study

Summary

The purpose of this study is to see if treatment of OSA with the CPAP device makes a difference to insulin resistance and heart disease.

Conditions

Interventions

DEVICE

CPAP Treatment

Effective CPAP treatment for one month

Sponsors & Collaborators

  • Ulysses Magalang MD

    lead OTHER

Principal Investigators

  • Ulysses Magalang, M.D. · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2013-10-31
Completion
2013-10-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01136122 on ClinicalTrials.gov